Final Announcement BBS Seminar Network meta-analysis: methods and applications

The BBS is pleased to host a half-day seminar on network meta-analysis methods and applications.
The talks will present recent methodological advances and challenges as well as case studies from
the pharmaceutical industry and academia. We welcome all quantitative scientists to this event, which
will be a great opportunity to meet with colleagues and exchange ideas on this emerging and vibrant
field.

The seminar is free of charge but registration is mandatory for organizational reasons. Please register
via email to fred.sorenson@xcenda.com by Tuesday, January 21st, 2020, the latest.

The seminar takes place on February 4th, 2020 from 13:00-17:30
Venue: Roche Auditorium Building 92, Grenzacherstrasse 124, 4070 Basel

Check out the event dedicated page for a summary of the day.

The BBS is pleased to host a full-day seminar on predictive modelling, machine learning, and causality with several eminent speakers. The talks will present recent methodological advances and challenges as well as case studies from the pharmaceutical industry and academia. We welcome all quantitative scientists to this event which will be a great opportunity to meet with colleagues and exchange ideas on this emerging and vibrant field.

The seminar is free of charge but registration is mandatory for organizational reasons. Please register via email to fred.sorenson@xcenda.com by Friday, October 18, 2019, the latest.

Date: Friday, November 1st, 2019, 08:30-16:45

Venue: Auditorium Roche Builing 683, Viaduktstrasse 31-35, Basel

Full program in pdf – with abstracts

Meeting agenda in pdf

Slide decks

Ewout Steyerberg, Clinical prediction models in the age of artificial intelligence and big data

Willi Sauerbrei, The EQUATOR networkand guidelines for prediction models

Torsten Hothorn, Score-based transformation learning

Peter Bühlmann, Causal regularization for distributional robustness and replicability

Giusi Moffa, Predicting putative intervention effects after causal structure learning from survey data

Andrew Shattock, Using machine learning and disease models to evaluate target product profiles of novel interventions (No slide deck available)

FedericoMattiello, Identifying high-risk patients in Non-Hodgkin lymphoma (and trying to get insights into the disease biology)

Mark Baillie, Novartis benchmarking initiative: making sense of AI

Chris Harbron, Experiences from running internal prediction challenges within a pharmaceutical company

August 21, 2019 from 9:00 – 16:00
Location: Roche, Building 001, Auditorium 2nd Floor

This Seminar is free of charge.
Please register via the BES homepage
Registration closes on August 9, 2019

Agenda

Miguel Hernan, Beyond intention-to-treat. Causal inference guidelines for causal inference
Christine Fletcher, The Final ICH E9(R1) E9 addendum
Frank Pétavy, A regulator’s perspective
Valentine Jehl, Adverse reactions confounded by prior medication: (how) can causal inference solve the problem? (No slide deck available)
Thibaut Sanglier, Treatment sequencing and effectiveness: challenges and considerations (No slide deck available)
Nikolaos Sfikas, Principal stratification techniques in the context of regulatory decision making (No slide deck available)
Jack Bowden, Implementing the Principal Stratum estimand strategy using Instrumental Variable methods: An emulation of the CANTOS trial

Date: August 19-20, 2019
Time: 9:00 – 17:00
Location: Roche Auditorium, Building 001, Auditorium 2nd Floor Fee: Industry: CHF 200 / Academia: CHF 100 / Students: 10 seats available free of charge
Registration: By e-mail to fred.sorenson@xcenda.com

Flyer

Final announcement

Precision medicine aims to tailor disease prevention, diagnosis and treatment to the individual patient, based on their individual features extracted from multiple types of data (such as multi-omics, imaging, patient history, lifestyle and environmental factors).

Advances in screening platforms and the availability of big data are fueling the scientific progress in precision medicine, spanning the early stage of drug discovery all the way through translation into clinical practice. Adequate use of statistical and computational methods are critical to its successful implementation in clinics.

The Basel Biometric Section (BBS) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) are pleased to host a European scientific meeting on this relevant and far-reaching topic. The purpose is to bring together experts from the pharmaceutical industry, academia and the European regulatory bodies to present the current state of the art and discuss the challenges and opportunities ahead.

The seminar takes place on June 4, 2019 from 9:00-17:00
Venue: Actelion Pharmaceuticals, Hegenheimermattweg 95, Allschwil, Switzerland

TO REGISTER PLEASE GO TO: www.efspi.org

Presentations

Niko Beerenwinkel, Bioinformatics for precision oncology (slide deck not available)

Stephen Senn, Precision medicine: The honeymoon is over. It’s high time for tough love

Tomasz Burzykowski, Generalized pairwise comparisons for precision medicine

Adam Heathfield, Valuation of Regenerative Medicine/Advance Therapeutics (RM/ATs): Challenges and opportunities for creating a better framework

JackKuipers, Mutational interactions define novel cancer subgroups: can they inform precision oncology?

Mario Ouwens, Difficulties with network meta-analysis when starting to use PDL1 thresholds

Georgina Bermann, Cardiovascular medicine: approaches to the use of early biomarker response to identify a patient subgroup with enhanced therapeutic benefit

Laurent Essioux, Examples of personalized Healthcare at Roche: statistical perspectives

Final Announcement BBS Spring Seminar Synthetic controls – what do we need and how far can we go?

The seminar takes place on May 10, 2019 from 9:00-16:30
Venue: Roche Auditorium, Viaduktstrasse, Basel

The seminar is free of charge. For organizational reasons please register by sending an email in advance to fred.sorenson@xcenda.com
Registration will close by Friday, April 26, 2019

Tom Brookland, RWD/RWE Global Regulatory Overview
Kaspar Rufibach and Hans Ulrich Burger, External controls in drug development
Somnath Sarkar, Considerations for Developing External Control Arm from Real-World Data
Laurence Colin and Yue Li, Making better use of early phase safety data
Cornelia Dunger-Baldauf, For the sake of the patient – reducing placebo exposure by using historical controls
Gonzalo Duran-Pacheco, Electronic Health Records used to derive Control Arms for Single-Arm oncology trials: Proof of concept using RCT’s in lung cancer
Chris Harbron, A Decision Making Framework For Utilising External Control Arms
Meinhard Kieser, Synthetic controls – what do we need and how far can we go? Rejoinder
Norbert Benda, Synthetic controls – what do we need and how far can we go? Rejoinder
Kit Roes, Synthetic controls – what do we need and how far can we go? Rejoinder
Jan Müller-Berghaus, Synthetic controls – what do we need and how far can we go? Rejoinder
(no slide deck available)
Anja Schiel, Synthetic controls – what do we need and how far can we go? Rejoinder
(no slide deck available)

Program

Date: Tuesday, June 26, 2018, 15:30-17.45
Venue: Auditorium Building 71, Roche Campus, Grenzacherstrasse, Basel

The BBS would like to offer a half-day seminar on topics related to clinical trials and personalized medicine with three eminent speakers. All talks will be accessible to general biostatisticians and highlight the relevance of these topics for clinical research and drug development.

The seminar is free of charge. For registration however please send an informal e-mail to Laurence Guillier (laurence.guillier@roche.com) or Barbora Martinec (barbora.martinec@roche.com) until 19th June.

Tomasz Burzykowski, Evaluation of Time-to-event Surrogate Endpoints Using Accelerated Failure-time Models
Everardo D. Saad, Precision Medicine Needs Randomized Trials
Marc Buyse, A statistical approach for personalized medicine and benefit / risk assessment

Final Announcement

BBS Spring Seminar New developments in HTA, adaptive designs and multiplicity – in remembrance of Willi Maurer

The Seminar fee is 100 CHF for industry and free for all others
Please register by sending an email in advance to fred.sorenson@xcenda.com
Registration will close by Friday, April 13, 2018

The seminar takes place on April 17, 2018 from 9:00-17:00
Novartis Auditorium, Fabrikstrasse 15

Jason Wang, Sense and sensibility of estimands for health technology assessment (HTA)
Christoph Gerlinger, EQ-5D-5L Utility Index for different countries
Susan Edwards, Whose perspective? Implications on cost-effectiveness modelling of differences between country value sets (a case study)
Carsten Schwenke, Real World Evidence and HTA – Experiences with IQWiG
Tim Friede, HTA AND SAFETY Some results of the ATF / APF Project Group, an ongoing empirical investigation and some personal views

Announcement BBS Seminar Competing Risks and Multi-State Models: Overview and Case Studies

The BBS would like to offer a half-day seminar on competing risks and multi-state models. The seminar will provide an overview of these topics by academic speakers and several case studies from industry and academia. All talks will be accessible to general biostatisticians and highlight the relevance of these topics for clinical research and drug development.

Scientific committee: Dietrich Knoerzer (Roche), Amanda Ross (Swiss TPH), Kaspar Rufibach (Roche), Marc Vandemeulebroecke (Novartis), Simon Wandel (Novartis), Marcel Wolbers (Roche)

The seminar is free of charge. For registration however please send an informal e-mail to Laurence Guillier (laurence.guillier@roche.com) or Barbora Martinec (barbora.martinec@roche.com).

The seminar takes place on March 20, 2018 13:30-17:15.
Venue: Room “Kilimanjaro”, Swiss TPH, Socinstrasse 57, Basel

Claudia Schmoor, Competing risks with applications to oncology
Jan Beyersmann, Analysis of co-time-to-event outcomes in randomized clinical trials
Ekkehard Glimm and Lillian Yau, A discrete semi-Markov model for the effect of need-based treatments on the disease states